LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND as Trustee SIXTH SUPPLEMENTAL INDENTURE DATED AS OF NOVEMBER 1, 2013Indenture • November 1st, 2013 • Laboratory Corp of America Holdings • Services-medical laboratories • New York
SIXTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 1, 2013 between Laboratory Corporation of America Holdings, a Delaware corporation (or its permitted successor) (the “Company”), and U.S. Bank National Association, as Trustee under the Indenture (the “Trustee”).
Laboratory Corporation of America Holdings $400,000,000 2.50% Senior Notes Due 2018 $300,000,000 4.00% Senior Notes Due 2023 Underwriting AgreementLaboratory Corp of America Holdings • November 1st, 2013 • Services-medical laboratories • New York
Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Fifth Supplemental Indenture and the Sixth Supplemental Indenture to be dated November 1, 2013 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Bas
